Hepion Pharmaceuticals Inc (HEPA)

[Couch]

EDISON, N.J., April 25, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. ( CTRV
) (“ContraVir”) , a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced the pricing of an underwritten public offering of common stock and warrants to purchase common stock, with anticipated gross proceeds of $12 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraVir. ContraVir is offering 12,000,000 shares of its common stock and warrants to purchase 6,000,000 shares of its common stock at a combined offering price of $1.00. All of the shares and warrants are being offered by ContraVir. The shares of common stock and warrants will be issued separately. The warrants will be exercisable beginning on the date of issuance for a period of five years from the issuance date at an exercise price of $1.25 per share. There is no established public trading market for the warrants and ContraVir does not expect a market to develop in the future. The offering is expected to close on or about April 28, 2017, subject to customary closing conditions. ContraVir intends to use the net proceeds from the sale of the securities to fund research and development activities, including ongoing clinical trials, and for working capital and other general corporate purposes, and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated.

RSI under 30 but beginning to point up slightly -- 3.5 million volume today -- 90 DAV = 828,750

Anyone know why the stock has dipped so far below the issuance PPS???